Signed in as:
filler@godaddy.com
EVENTS IN MARCH
EpiHeart is present at TechTour European Healthtech Investment Forum in Helsinki, Finland, as one of the startups selected to give a pitch. Company is also representing at sTARTUp Day event in Tartu, Estonia.
CE approval
Our devices for autologous epicardial cellular therapy have been CE-marked according to the European Medical Device Regulation. The CE approval of the four unique devices marks an important step in enabling cellular therapies in clinical settings. Contact us to learn more on how to take cellular therapy into practice!
EACTS 2022
Our team was present at the exhibition of EACTS - European Association for Cardio-Thoracic Surgery - annual meeting 5.-8.10.2022 in Milan, Italy. A lot has happened since the conference last year, and we were delighted of the interest and insightful discussions with medical professionals from all over the world!
FIRST CLINICAL USE MILESTONE ACHIEVED
Helsinki, Hannover, 25.8.2022
First patient cases always mark a major milestone for medical device companies in the development of novel treatments and devices. We reached this milestone last week when first patient was treated with EpiHeart’s medical devices to provide cardiac cellular therapy leveraging autologous left atrial appendage derived microtissues. The treatment was given as a part of left ventricular assist device (LVAD) surgery by Professor Dr. Jan Schmitto and his interdisciplinary Heart-Team at MHH (Medizinische Hochschule Hannover) in Hannover, Germany.
Patients receiving LVAD are commonly very sick as their heart failure has progressed so far that a lifesaving pump is needed to support the blood flow. Often LVAD implantation is used to provide functional support for the failing heart before heart transplantation as patients wait for suitable donor hearts. This patient group is relevant for microtissue-based cellular therapies for two reasons. Firstly, there is a vast clinical need to support both sides of the failing heart. Secondly, as some of the patients will later receive heart transplants, the biological effects of the epicardial cellular therapy can be evaluated utilizing the latest state-of-the-art molecular and cellular analyses.
“Based on this successful case experience, a larger clinical study is being prepared. We are looking forward to a promising and continued collaboration between our team at MHH and EpiHeart.” - Prof. Dr. Jan Schmitto
Further information may be requested:
Kai Kronström, EpiHeart CEO, info@epiheart.com
EUMS 2022
EpiHeart was present at the European Mechanical Circulatory Support Summit in Hannover, Germany 24.-27.5.2022. Thank you to the organizing committee and all participants at Schloss Herrenhausen for insightful discussions!